Is The Trade Desk a Screaming Buy?
One factor that sets programmatic advertising platform The Trade Desk…
Buy
71
TGTX Quote, Financials, Valuation and Earnings
Last price:
$37.01
Seasonality move
:
9.34%
Day range:
$37.59 - $38.92
52-week range:
$12.93 - $43.32
Dividend yield:
0%
P/E ratio:
273.71x
P/S ratio:
18.25x
P/B ratio:
27.07x
Volume:
1.1M
Avg. volume:
3.1M
1-year change:
177.28%
Market cap:
$6B
Revenue:
$329M
EPS (TTM):
$0.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
$117.1M | $0.16 | 77.29% | 743.75% | $43.00 |
|
ADMA
ADMA Biologics
|
$116.4M | $0.14 | 42.17% | 75% | $25.74 |
|
CMRX
Chimerix
|
-- | -$0.27 | 7665% | -8% | $8.54 |
|
OCGN
Ocugen
|
-- | -$0.06 | -100% | -- | $6.75 |
|
OCUL
Ocular Therapeutix
|
$16.9M | -$0.28 | 16.58% | -42.86% | $17.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
$38.32 | $43.00 | $6B | 273.71x | $0.00 | 0% | 18.25x |
|
ADMA
ADMA Biologics
|
$21.31 | $25.74 | $5.1B | 25.99x | $0.00 | 0% | 12.14x |
|
CMRX
Chimerix
|
$8.54 | $8.54 | $801.1M | -- | $0.00 | 0% | -- |
|
OCGN
Ocugen
|
$0.68 | $6.75 | $198.4M | -- | $0.00 | 0% | 45.40x |
|
OCUL
Ocular Therapeutix
|
$7.31 | $17.50 | $1.2B | -- | $0.00 | 0% | 18.15x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
52.36% | 1.750 | 5.21% | 4.85x |
|
ADMA
ADMA Biologics
|
17.17% | 2.782 | 1.78% | 2.76x |
|
CMRX
Chimerix
|
-- | -9.573 | -- | 5.55x |
|
OCGN
Ocugen
|
49.18% | 1.424 | 12.22% | 2.71x |
|
OCUL
Ocular Therapeutix
|
17.85% | 2.429 | 5.09% | 10.26x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
$92.8M | $29.9M | 6.86% | 12.81% | 30.05% | -$25.7M |
|
ADMA
ADMA Biologics
|
$63.3M | $38.3M | 60.85% | 93.41% | 31.98% | $47.5M |
|
CMRX
Chimerix
|
-- | -$24.6M | -56.64% | -56.65% | -43073.68% | -$19.4M |
|
OCGN
Ocugen
|
-- | -$13.8M | -136.46% | -171.04% | -1811.52% | -$10.4M |
|
OCUL
Ocular Therapeutix
|
$15.9M | -$50.6M | -51.22% | -62.66% | -265.09% | -$39.6M |
TG Therapeutics vs. Competitors
-
Which has Higher Returns TGTX or ADMA?
ADMA Biologics has a net margin of 21.57% compared to TG Therapeutics's net margin of 95.19%. TG Therapeutics's return on equity of 12.81% beat ADMA Biologics's return on equity of 93.41%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M ADMAADMA Biologics53.88% $0.46 $421.4M -
What do Analysts Say About TGTX or ADMA?
TG Therapeutics has a consensus price target of $43.00, signalling upside risk potential of 12.21%. On the other hand ADMA Biologics has an analysts' consensus of $25.74 which suggests that it could grow by 20.79%. Given that ADMA Biologics has higher upside potential than TG Therapeutics, analysts believe ADMA Biologics is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 ADMAADMA Biologics3 1 0 -
Is TGTX or ADMA More Risky?
TG Therapeutics has a beta of 2.139, which suggesting that the stock is 113.867% more volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.277%.
-
Which is a Better Dividend Stock TGTX or ADMA?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or ADMA?
TG Therapeutics quarterly revenues are $108.2M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. TG Therapeutics's net income of $23.3M is lower than ADMA Biologics's net income of $111.9M. Notably, TG Therapeutics's price-to-earnings ratio is 273.71x while ADMA Biologics's PE ratio is 25.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 18.25x versus 12.14x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics18.25x 273.71x $108.2M $23.3M ADMAADMA Biologics12.14x 25.99x $117.5M $111.9M
-
Which has Higher Returns TGTX or CMRX?
Chimerix has a net margin of 21.57% compared to TG Therapeutics's net margin of -40270.18%. TG Therapeutics's return on equity of 12.81% beat Chimerix's return on equity of -56.65%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M CMRXChimerix-- -$0.25 $121.7M -
What do Analysts Say About TGTX or CMRX?
TG Therapeutics has a consensus price target of $43.00, signalling upside risk potential of 12.21%. On the other hand Chimerix has an analysts' consensus of $8.54 which suggests that it could fall by --. Given that TG Therapeutics has higher upside potential than Chimerix, analysts believe TG Therapeutics is more attractive than Chimerix.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 CMRXChimerix1 3 0 -
Is TGTX or CMRX More Risky?
TG Therapeutics has a beta of 2.139, which suggesting that the stock is 113.867% more volatile than S&P 500. In comparison Chimerix has a beta of -0.176, suggesting its less volatile than the S&P 500 by 117.551%.
-
Which is a Better Dividend Stock TGTX or CMRX?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chimerix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Chimerix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or CMRX?
TG Therapeutics quarterly revenues are $108.2M, which are larger than Chimerix quarterly revenues of $57K. TG Therapeutics's net income of $23.3M is higher than Chimerix's net income of -$23M. Notably, TG Therapeutics's price-to-earnings ratio is 273.71x while Chimerix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 18.25x versus -- for Chimerix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics18.25x 273.71x $108.2M $23.3M CMRXChimerix-- -- $57K -$23M
-
Which has Higher Returns TGTX or OCGN?
Ocugen has a net margin of 21.57% compared to TG Therapeutics's net margin of -1816.75%. TG Therapeutics's return on equity of 12.81% beat Ocugen's return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M OCGNOcugen-- -$0.05 $58.3M -
What do Analysts Say About TGTX or OCGN?
TG Therapeutics has a consensus price target of $43.00, signalling upside risk potential of 12.21%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 893.52%. Given that Ocugen has higher upside potential than TG Therapeutics, analysts believe Ocugen is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 OCGNOcugen2 0 0 -
Is TGTX or OCGN More Risky?
TG Therapeutics has a beta of 2.139, which suggesting that the stock is 113.867% more volatile than S&P 500. In comparison Ocugen has a beta of 3.784, suggesting its more volatile than the S&P 500 by 278.402%.
-
Which is a Better Dividend Stock TGTX or OCGN?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or OCGN?
TG Therapeutics quarterly revenues are $108.2M, which are larger than Ocugen quarterly revenues of $764K. TG Therapeutics's net income of $23.3M is higher than Ocugen's net income of -$13.9M. Notably, TG Therapeutics's price-to-earnings ratio is 273.71x while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 18.25x versus 45.40x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics18.25x 273.71x $108.2M $23.3M OCGNOcugen45.40x -- $764K -$13.9M
-
Which has Higher Returns TGTX or OCUL?
Ocular Therapeutix has a net margin of 21.57% compared to TG Therapeutics's net margin of -283.27%. TG Therapeutics's return on equity of 12.81% beat Ocular Therapeutix's return on equity of -62.66%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M OCULOcular Therapeutix92.8% -$0.29 $383.8M -
What do Analysts Say About TGTX or OCUL?
TG Therapeutics has a consensus price target of $43.00, signalling upside risk potential of 12.21%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 139.4%. Given that Ocular Therapeutix has higher upside potential than TG Therapeutics, analysts believe Ocular Therapeutix is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 OCULOcular Therapeutix6 0 0 -
Is TGTX or OCUL More Risky?
TG Therapeutics has a beta of 2.139, which suggesting that the stock is 113.867% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.133%.
-
Which is a Better Dividend Stock TGTX or OCUL?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or OCUL?
TG Therapeutics quarterly revenues are $108.2M, which are larger than Ocular Therapeutix quarterly revenues of $17.1M. TG Therapeutics's net income of $23.3M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, TG Therapeutics's price-to-earnings ratio is 273.71x while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 18.25x versus 18.15x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics18.25x 273.71x $108.2M $23.3M OCULOcular Therapeutix18.15x -- $17.1M -$48.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is IQQQ High Income ETF Good to Buy?
The Proshares NASDAQ-100 High Income ETF (IQQQ) is a covered…
Can Spotify Ever Become Consistently Profitable?
Spotify (NYSE:SPOT) owns more than 30% market share as the most…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
23
UNH alert for Apr 21
UnitedHealth Group [UNH] is down 6.42% over the past day.
Sell
30
MAN alert for Apr 21
ManpowerGroup [MAN] is down 0.22% over the past day.
Sell
24
GPN alert for Apr 21
Global Payments [GPN] is down 2.84% over the past day.
